NASDAQ:KROS
Keros Therapeutics, Inc.
Keros Therapeutics, Inc.'s revenue was $243.9M in fiscal 2025. Free cash flow was $106.0M, 43.4% of revenue, and the diluted share count rose 1.1%.Summary generated from Keros Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 4, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$243.9M
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin27.7%
Net margin35.7%
ROICn/a
Return on equity19.9%
Debt / equityn/a
Free cash flow$106.0M
FCF margin43.4%
Share count change+1.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 20 | 0 | 0 | 0 | 244 |
| Operating income | −56 | −115 | −170 | −211 | 68 |
| Net income | −59 | −105 | −153 | −187 | 87 |
| Free cash flow | −63 | −71 | −127 | −163 | 106 |
Recent filings
- 8-KRegulation FD disclosure
Sep 29, 2026 - 8-KRegulation FD disclosure
Sep 28, 2026 - 8-KOther events
Sep 8, 2026 - 4Insider transaction report
Aug 20, 2026 - 4Insider transaction report
Aug 20, 2026 - 8-KRegulation FD disclosure
Aug 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 3, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026